Evidence map›Paper›PMID 39206106›Full record

ArticleJournal of clinical medicine research2024

Renin-Angiotensin System Genes Polymorphisms in Patients With COVID-19 and Its Relation to Severe Cases of SARS-CoV-2 Infection.

Anna E Bragina, Aida I Tarzimanova, Yulia N Rodionova, Ekaterina S Ogibenina, Aleksandr Yu Suvorov, Natalya A Druzhinina, Lyubov V Vasilyeva, Tatiana I Ishina, Ivan D Medvedev, Marina S Borlakova and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anna E Bragina2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0000-0002-2699-1610
Aida I Tarzimanova2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0000-0001-9536-8307
Yulia N Rodionova2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0000-0003-3461-6703
Ekaterina S OgibeninaUniversity Clinical Hospital #4, I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0000-0002-2129-818X
Aleksandr Yu SuvorovWorld-Class Research Center "Digital biodesign and Personalized Healthcare", Sechenov First Moscow State Medical University, Moscow, Russia.ORCID https://orcid.org/0000-0002-2224-0019
Natalya A Druzhinina2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0000-0001-8397-0210
Lyubov V Vasilyeva2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0000-0001-5730-7837
Tatiana I Ishina2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0000-0001-7720-0770
Ivan D Medvedev2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0000-0003-4210-2841
Marina S BorlakovaDepartment of Pharmacology, Institute of Digital Biodesign and Modeling of Living Systems, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0009-0008-2222-5602
Anastasiia R Komelkova2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0009-0007-9789-4221
Daria V Gushchina2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0009-0000-7908-9092
Artem A Khachaturov2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.ORCID https://orcid.org/0009-0000-0711-9619
Valery I Podzolkov2nd Internal Medicine (2nd Faculty Therapy) Department, N.V. Sklifosovskiy Institute of Clinical Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Different variants of single nucleotide polymorphisms (SNPs) of angiotensinogen (AGT), angiotensin-converting enzyme type 1 (ACE1), and angiotensin II receptors type 1 (AGTR1) and 2 (AGTR2) genes determine different susceptibility to cardiovascular disease (CVD) and hypertension, which can be considered as risk factors for fatal outcomes among coronavirus disease 2019 (COVID-19) patients. The objective of our study was to assess the relation between the frequency of SNPs of the renin-angiotensin system (RAS) components, and the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods: The cross-sectional study included 100 patients with a laboratory-confirmed diagnosis of COVID-19 admitted to the hospital. Criteria for severe COVID-19 included respiratory rate (RR) > 30/min, blood oxygen saturation (SpO Results: Patients were divided into groups with severe (n = 44) and moderate COVID-19 (n = 56). For ACE1 rs1799752, a significant deviation from the population distribution was detected in both studied subgroups. A higher frequency of the C allele SNP rs5186 AGTR1 gene was detected in the group with severe disease. More frequent A/A genotype of SNP rs1403543 AGTR2 was detected among females with severe COVID-19. Haplotype analysis revealed more common DCG haplotype among patients with severe COVID-19. The odds ratio for severe COVID-19 in the presence of the DCG haplotype was 3.996 (95% confidential interval: 1.080 -14.791, P < 0.05). Conclusions: Our data suggest that the SNP genes of the RAS components, may allow to identify groups of patients predisposed to a more severe course of COVID-19.

Indexed as

Angiotensin-converting enzyme type 1 geneAngiotensin II receptor type 1 geneAngiotensin II receptor type 2 geneAngiotensinogen geneCOVID-19SARS-CoV-2 infectionSingle nucleotide polymorphisms

Identifiers

PMID39206106
PMCPMC11349126

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.